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eters (1). Any one of these devices can
be combined with the transjugular intra-
hepatic portal vein catheter technique.
This hypothesis seems to us worthy of
testing in clinical trials.
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Re: Alcohol Dehydrogenase 3
Genotype and Risk of Oral
Cavity and Pharyngeal
Cancers
Recently, Harty et al. (1) reported in
the Journal that alcohol dehydrogenase
type 3 (ADH3), a polymorphic enzyme
that metabolizes ethanol to acetalde-
hyde, modified the risk of development
of oropharyngeal cancers in a cohort of
Puerto Ricans who had high levels of
alcohol consumption.
We investigated whether these find-
ings could be reproduced in another
population, from part of a hospital-
based, case–control study performed in
France among Caucasians (2). In our
study, only case subjects (n 4 165) with
histologically confirmed squamous car-
cinoma of the oral cavity and pharynx
were included. Control subjects (n 4
234) were individuals without a history
of cancer and were frequency matched
for sex, age, and hospital.
The main conditions diagnosed
among control subjects were rheumato-
logic (n 4 74; 32%), infectious and
parasitic (n 4 24; 10%), respiratory (n
4 21; 9%), cardiovascular (n 4 19;
8%), and digestive (n 4 14; 7%) dis-
eases as well as traumatic injuries (n 4
12; 5%). Severe liver diseases were ex-
clusion criteria for both case subjects
and control subjects.
ADH3 genotypes were determined
with the use of a polymerase chain re-
action DNA amplification assay (3) for
68 patients with oral cavity cancer, 51
patients with pharyngeal cancer, and
167 control subjects. Genotype determi-
nations were performed by investigators
who were blinded to the source of the
specimens.
Lifetime use of tobacco (cigarettes,
cigars, or pipe) and alcohol consumption
were recorded during a personal inter-
view conducted by seven trained inter-
viewers. Alcohol beverages were con-
verted into grams of pure ethanol, and
the average daily consumption was cal-
culated by dividing the cumulative life-
time consumption by the overall dura-
tion of drinking. Odds ratios (ORs) were
calculated by unconditional logistic re-
gression, including sex, age, and smok-
ing as confounding factors. The interac-
tion between ADH3 genotype (ADH31–1
versus ADH31–2 or ADH32–2) and levels
of daily alcohol consumption was stud-
ied to test the equality of the effect of
ADH3 genotypes across the drinking
levels (4). To this end, the average daily
consumption of alcohol was divided ac-
cording to the approximated quartile
distribution observed among the control
subjects.
The risk of oropharyngeal cancer as-
sociated with the ADH31–1 genotype,
compared with the ADH31–2 and the
ADH32–2 genotypes combined, was
slightly, although not significantly, in-
creased (OR 4 1.4; 95% confidence in-
terval 4 0.8–2.3) (Table 1). The risk of
cancer rose significantly with increased
daily consumption of alcohol (x2 two-
Table 1. Number of case and control subjects* and odds ratios† (95% confidence intervals) of
oropharyngeal cancer according to ADH3 genotypes and alcohol consumption‡
ADH3 genotype
Average consumption of ethanol§
Total§,\ø40 g/day 41–80 g/day 81–120 g/day >120 g/day
ADH31–2 and ADH32–2 1 (referent) 2.3 (0.8–7.0) 3.4 (1.0–10.9) 5.8 (1.9–17.6) 1 (referent)
6/26 18/35 13/19 29/22 66/102
ADH31–1 1.7 (0.5–5.5) 3.4 (1.1–10.9) 5.3 (1.3–21.6) 6.3 (1.8–21.4) 1.4 (0.8–2.3)
10/23 14/19 8/7 17/11 49/60
Total¶ 1 (referent) 2.2 (1.0–4.6) 3.2 (1.3–7.5) 4.8 (2.2–10.7)
16/49 32/54 21/26 46/33
*Data on smoking (cigarettes, cigars, pipe) and/or alcohol exposure were missing for four case subjects
and five control subjects.
†Odds ratios are adjusted for sex, age, and exposure to smoking (cigarettes, cigars, or pipe).
‡Interaction test between ADH3 genotypes and levels of alcohol consumption: x2 two-sided test for
homogeneity 4 0.4 for 3 degrees of freedom, P 4 0.94.
§Values in columns for each group 4 top line: odds ratio (95% confidence interval); bottom line:
number of case subjects/number of control subjects.
\Also adjusted for daily consumption of ethanol.
¶Also adjusted for ADH3 genotype.
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sided test for trend; P<.0001). No inter-
action was found between ADH3 geno-
type and alcohol consumption; i.e., the
effect of ADH3 genotype was the same
in each category of alcohol consumption
and vice versa. Similar results were ob-
served when the same cut points for the
number of alcoholic drinks per week
used by Harty et al. (1) were analyzed.
These findings do not support the
conclusion of a greater effect of
ADH31–1 genotype among the group of
subjects within our study group who had
the highest level of alcohol consump-
tion. This discrepancy between the con-
clusions of the two studies might be due
to mere chance, selection bias, or differ-
ences in the populations studied. Our re-
sults are consistent, however, with those
of Coutelle et al. (5), who reported a
slightly positive but not statistically sig-
nificant association between ADH31–1
and the risk of oropharyngeal cancer
among French Caucasian alcoholics.
The ADH3 allele frequencies among our
control subjects (0.57 for ADH31 and
0.43 for ADH32) were quite similar to
those reported for subjects in this other
French population (0.55 and 0.45, re-
spectively) (5), but they were slightly
different from those observed in the co-
hort of Puerto Rican subjects (0.62 and
0.38, respectively) studied by Harty et
al. (1). A limitation of our study would
be the use of hospital control subjects,
especially if there are any associations
between ADH3 genotypes and diseases
diagnosed. Nevertheless, the distribu-
tion of ADH3 genotypes was not signifi-
cantly different among the disease
groups, although the power to detect
such differences is low. Further studies
are needed to understand better the role
of ADH3 in susceptibility to alcohol-
related cancers.
CHRISTINE BOUCHARDY
CHRISTIANE COUTELLE
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Response
We thank Bouchardy et al. for bring-
ing to our attention their new data re-
garding the relationship of alcohol
drinking, alcohol dehydrogenase 3
(ADH3) genotype, and oral cancer.
However, the limited information they
provide makes comparisons between the
two studies difficult. Details are missing
regarding subjects’ age and sex; the ana-
tomic subsites of the tumors; whether
incident or prevalent cases were studied;
the method used to calculate alcohol in-
take; the types of alcoholic beverages
consumed; the distribution of alcohol in-
takes by case–control status, by ADH3
genotype, and by disease category for
the control subjects; the risks observed
with the use of a non-drinker referent
group; and the risks associated with
each of the following three ADH3 geno-
types: ADH31–1 (homozygous for the
fast-metabolizing ADH31 allele),
ADH31–2 (heterozygous), and ADH32–2
(homozygous for the slow-metabolizing
ADH32 allele).
In our study (1), we observed an ad-
justed risk for oral cancer of 1.3 (95%
confidence interval [CI] 4 0.8–2.4)
among subjects with the ADH31–1 geno-
type compared with subjects with the
ADH31–2 or the ADH32–2 genotype,
quite similar to the risk observed by
Bouchardy et al. (odds ratio [OR] 4
1.4; 95% CI 4 0.8–2.3). However,
Bouchardy et al. did not observe an in-
creased risk associated with the
ADH31–1 genotype among consumers
with the highest alcohol intakes, in con-
trast to our study (1). We note that the
alcohol-related risk of oral cancer was
higher for heavy drinkers (ù57 drinks/
week) in Puerto Rico (OR 4 13.1; 95%
CI 4 3.9–44.2) (1) than for heavy
drinkers (>120 g/day [approximately
>70 drinks/week]) in France (OR 4 4.8;
95% CI 4 2.2–10.7), which may be due
to the use of different referent groups (0
drinks/week in our study; ø40 g/day
[approximately ø23 drinks/week] in the
study by Bouchardy et al.), differences
in alcohol use (i.e., amounts, patterns of
use, or beverage types), or misclassifi-
cation in the exposure assessment. Like
Bouchardy et al., we (1) observed no
additional risk associated with the
ADH3 genotype at intakes associated
with risks up to OR 4 4.7 (95% CI 4
1.6–14.4).
A particular concern is that individu-
als with severe liver disease were ex-
cluded from the study by Bouchardy et
al. but not from our study (1). The rela-
tionships between ADH3 genotype, liver
damage, alcohol intake, and ADH activ-
ity are unresolved (2–6) and potentially
complex. If liver damage and ADH31–1
genotype are positively associated, ex-
cluding subjects with severe liver dis-
ease will undersample heavy drinkers
with the ADH31–1 genotype. While de-
tails regarding the exclusion criteria are
not given by Bouchardy et al., case–
control differences could have biased
the results toward the null.
We interpret the only other study (6)
of ADH3 genotype, alcohol intake, and
oropharyngeal cancer as suggesting that
heavy drinkers with the ADH31–1 geno-
type may have an elevated risk of upper
aerodigestive tract cancers compared
with those with the ADH31–2 or the
ADH32–2 genotype. Coutelle et al. (6)
reported a 2.6-fold (95% CI 4 0.7–
10.0) higher risk of oropharyngeal can-
cer and a 6.1-fold (95% CI 4 1.3–28.6)
higher risk of laryngeal cancer associ-
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